Total Payments
$601,095
2024 Payments
$175,573
Companies
48
Transactions
1,500
Medicare Patients
1,276
Medicare Billing
$167,640
Payment Breakdown by Category
Other$395,578 (65.8%)
Consulting$116,247 (19.3%)
Travel$52,341 (8.7%)
Food & Beverage$36,758 (6.1%)
Education$171.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $386,567 | 168 | 64.3% |
| Consulting Fee | $116,247 | 73 | 19.3% |
| Travel and Lodging | $52,341 | 125 | 8.7% |
| Food and Beverage | $36,758 | 1,121 | 6.1% |
| Honoraria | $5,031 | 2 | 0.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,980 | 3 | 0.7% |
| Education | $171.46 | 8 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $115,747 | 197 | $0 (2024) |
| LEO Pharma Inc. | $103,354 | 180 | $0 (2024) |
| Galderma Laboratories, L.P. | $91,124 | 191 | $0 (2024) |
| Amgen Inc. | $82,765 | 131 | $0 (2024) |
| Incyte Corporation | $51,517 | 73 | $0 (2024) |
| Celgene Corporation | $38,979 | 89 | $0 (2020) |
| Arcutis Biotherapeutics, Inc. | $35,332 | 60 | $0 (2024) |
| Verrica Pharmaceuticals Inc. | $23,985 | 18 | $0 (2024) |
| Promius Pharma LLC | $16,728 | 28 | $0 (2019) |
| Dermavant Sciences, Inc. | $14,870 | 51 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $175,573 | 327 | LEO Pharma Inc. ($70,088) |
| 2023 | $149,114 | 302 | Galderma Laboratories, L.P. ($36,340) |
| 2022 | $60,737 | 182 | Amgen Inc. ($24,386) |
| 2021 | $22,136 | 108 | Amgen Inc. ($16,136) |
| 2020 | $17,267 | 60 | Amgen Inc. ($6,446) |
| 2019 | $50,998 | 150 | PFIZER INC. ($22,249) |
| 2018 | $60,784 | 200 | PFIZER INC. ($28,781) |
| 2017 | $64,487 | 171 | PFIZER INC. ($26,377) |
All Payment Transactions
1,500 individual payment records from CMS Open Payments — Page 1 of 60
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $50.00 | General |
| Category: Inflammation | ||||||
| 12/20/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | Cash or cash equivalent | $33.34 | General |
| Category: Inflammation | ||||||
| 12/20/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $4.36 | General |
| Category: Dermatology | ||||||
| 12/19/2024 | LEO Pharma Inc. | ADBRY (Biological) | Consulting Fee | Cash or cash equivalent | $1,390.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/19/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $149.97 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $9.86 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | LEO Pharma Inc. | ADBRY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,128.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $9.46 | General |
| Category: Inflammation & Immunology | ||||||
| 12/12/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/11/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Travel and Lodging | In-kind items and services | $756.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/11/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Food and Beverage | In-kind items and services | $26.41 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $32.81 | General |
| Category: Immunology | ||||||
| 12/09/2024 | LEO Pharma Inc. | ADBRY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,560.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | LEO Pharma Inc. | ADBRY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,780.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | Galderma Laboratories, L.P. | DYSPORT | Food and Beverage | In-kind items and services | $25.23 | General |
| 12/09/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $12.04 | General |
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $132.52 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $6.65 | General |
| Category: DERMATOLOGY | ||||||
| 12/04/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $58.28 | General |
| Category: DERMATOLOGY | ||||||
| 12/04/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Inflammation & Immunology | ||||||
| 12/03/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: DERMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 425 | 785 | $108,120 | $60,509 |
| 2022 | 8 | 267 | 476 | $48,985 | $26,944 |
| 2021 | 10 | 309 | 544 | $73,645 | $43,804 |
| 2020 | 9 | 275 | 4,595 | $68,119 | $36,383 |
Total Patients
1,276
Total Services
6,400
Medicare Billing
$167,640
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 27 | 46 | $22,333 | $13,356 | 59.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 75 | 115 | $19,679 | $10,715 | 54.4% |
| 96573 | Application of light by qualified health care professional to destroy precancer skin growth | Office | 2023 | 28 | 47 | $10,904 | $8,548 | 78.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $10,598 | $5,549 | 52.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 52 | $7,202 | $4,906 | 68.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 18 | 29 | $7,762 | $4,114 | 53.0% |
| 12031 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | Office | 2023 | 11 | 15 | $5,413 | $3,583 | 66.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 41 | 51 | $7,564 | $3,411 | 45.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 65 | 81 | $9,859 | $2,669 | 27.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 23 | 48 | $3,830 | $2,191 | 57.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 50 | 255 | $2,976 | $1,469 | 49.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 44 | 44 | $10,138 | $5,790 | 57.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 51 | $7,064 | $5,396 | 76.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 40 | 55 | $9,412 | $5,330 | 56.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 41 | 50 | $7,416 | $3,748 | 50.5% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 13 | 16 | $4,283 | $2,462 | 57.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 39 | 49 | $5,964 | $1,655 | 27.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 16 | 33 | $2,633 | $1,498 | 56.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 35 | 178 | $2,077 | $1,065 | 51.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 67 | 108 | $14,958 | $11,465 | 76.6% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2021 | 13 | 23 | $11,167 | $7,078 | 63.4% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 35 | 52 | $8,898 | $5,235 | 58.8% |
| 96573 | Application of light and light-sensitive drugs to aid destruction of premalignant skin growths, per day | Office | 2021 | 13 | 25 | $5,800 | $4,640 | 80.0% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 27 | 35 | $9,368 | $4,064 | 43.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 31 | 31 | $7,142 | $3,928 | 55.0% |
About Dr. Michelle Ehrlich, MD
Dr. Michelle Ehrlich, MD is a MOHS-Micrographic Surgery healthcare provider based in Manhattan Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1134244635.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michelle Ehrlich, MD has received a total of $601,095 in payments from pharmaceutical and medical device companies, with $175,573 received in 2024. These payments were reported across 1,500 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($386,567).
As a Medicare-enrolled provider, Ehrlich has provided services to 1,276 Medicare beneficiaries, totaling 6,400 services with total Medicare billing of $167,640. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty MOHS-Micrographic Surgery
- Other Specialties Dermatology
- Location Manhattan Beach, CA
- Active Since 03/21/2007
- Last Updated 05/13/2025
- Taxonomy Code 207ND0101X
- Entity Type Individual
- NPI Number 1134244635
Products in Payments
- Otezla (Drug) $108,655
- ADBRY (Biological) $102,597
- EUCRISA (Drug) $83,906
- OPZELURA (Drug) $51,517
- AKLIEF (Drug) $32,914
- CIBINQO (Drug) $29,688
- YCANTH (Drug) $23,985
- Zoryve (Drug) $20,307
- ORACEA (Drug) $17,691
- VTAMA (Drug) $14,870
- EPSOLAY (Drug) $10,503
- SOOLANTRA (Drug) $9,884
- Trianex (Drug) $6,832
- DUOBRII (Drug) $5,904
- MIRVASO (Drug) $4,017
- Cloderm Cream (Drug) $3,827
- Sernivo Spray (Drug) $2,770
- Sernivo Spray 120ml (Drug) $2,673
- RHOFADE (Drug) $1,795
- AMELUZ (Drug) $1,525
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.